PMS-DICLOFENAC 1.5 % — DIN 02356783
DICLOFENAC SODIUM : 1.5 % · PHARMASCIENCE INC · SOLUTION · wholesale supply in Canada
Health Canada status: DORMANT
What is PMS-DICLOFENAC?
PMS-DICLOFENAC 1.5 % contains DICLOFENAC SODIUM : 1.5 %. It is listed in the Health Canada Drug Product Database under DIN 02356783, held by PHARMASCIENCE INC, supplied as SOLUTION for TOPICAL administration. Health Canada currently lists it as dormant, status dated 31-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is PMS-DICLOFENAC used for?
Treatment of symptoms associated with osteoarthritis of the knee(s) for a duration of not more than three months.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Diclofenac cost around the world?
Diclofenac is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Belgium publishes a public; Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Morocco | PPV (public price) | 26 | 74 |
| United States | acquisition | 6 | 41 |
| Italy | prezzo al pubblico (classe A) | 28 | 40 |
| South Africa | single exit price | 25 | 35 |
| Australia | ex-manufacturer | 9 | 22 |
| Romania | max producer price | 15 | 21 |
| Greece | producer price (ex-factory) | 13 | 13 |
| United Kingdom | hospital | 10 | 10 |
| Hungary | producer price (ex-factory) | 2 | 3 |
| Belgium | public | 1 | 1 |
260 pack listings across 135 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Diclofenac pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Diclofenac in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Diclofenac, across 14 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| HALEON CANADA ULC | 6 | 5 | VOLTAREN EMULGEL, VOLTAREN EMULGEL ACTIVE, VOLTAREN EMULGEL BACK & MUSCLE PAIN, VOLTAREN EMULGEL EXTRA STRENGTH, VOLTAREN EMULGEL JOINT PAIN EXTRA STRENGTH, +1 more | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 2 | 1 | DICLOFENAC DIETHYLAMINE GEL EXTRA STRENGTH, TARO-DICLOFENAC | Sourceable in Canada |
| ENDO OPERATIONS LTD. | 1 | 1 | PENNSAID | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP DICLOFENAC TOPICAL SOLUTION | Sourceable in Canada |
| APOTEX INC | 1 | 0 | APO-DICLOFENAC | No marketed DIN |
| HIKMA CANADA LIMITED | 1 | 0 | DICLOFENAC SODIUM SOLUTION | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-DICLOFENAC | No marketed DIN |
| STERIMAX INC | 1 | 0 | DICLOFENAC TOPICAL SOLUTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1.5 % |
|---|---|
| Dosage form | SOLUTION |
| Route | TOPICAL |
| Pack configuration (monograph) | Low-density polyethylene bottles of 15, 30, and 60 mL; high-density polyethylene bottles of 15, 30, 60, and 120 mL with a plastic dropper cap. |
| Storage | Store at 15-30°C. (Note: General storage section 11 not fully provided in snippet, but standard for this product). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Diclofenac |
|---|---|
| ATC code | M02AA15 |
| AHFS class | 28:08.04.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02356783 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2356783 |
| Brand name | PMS-DICLOFENAC |
| Generic / active ingredient | DICLOFENAC SODIUM : 1.5 % |
| Market authorization holder | PHARMASCIENCE INC |
| Health Canada schedule | Prescription |
| ATC code | M02AA15 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M02AA |
| Current status | DORMANT |
| Status date | 31-Jul-2025 |
| Original market date | 2014-12-02 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Apply 50 drops per knee 3 times daily, or 40 drops per knee 4 times daily. Spread evenly on clean, dry skin. Maximum duration 3 months. External use only.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
CABG surgery peri-operative setting; hypersensitivity to diclofenac, NSAIDs, or DMSO; pregnancy; breastfeeding; pediatrics <18; severe heart failure; active peptic ulcer; ASA intolerance; severe hepatic/renal impairment.
Warnings and precautions
Increased risk of serious cardiovascular thrombotic events (MI, stroke) and serious gastrointestinal events (bleeding, ulceration, perforation). Risk of hepatotoxicity and hypertension.
Is Diclofenac in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by PHARMA STULLN INC., last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 14 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP DICLOFENAC TOPICAL SOLUTION | 1.5 % | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02472309 |
| PENNSAID | 1.5 % | SOLUTION | ENDO OPERATIONS LTD. | MARKETED | 02247265 |
| TARO-DICLOFENAC | 1.5 % | SOLUTION | TARO PHARMACEUTICALS INC | MARKETED | 02420988 |
| VOLTAREN EMULGEL ACTIVE | 1.16 % | GEL | HALEON CANADA ULC | MARKETED | 02554801 |
| VOLTAREN EMULGEL BACK & MUSCLE PAIN | 1.16 % | GEL | HALEON CANADA ULC | MARKETED | 02465035 |
| VOLTAREN EMULGEL EXTRA STRENGTH | 2.32 % | GEL | HALEON CANADA ULC | MARKETED | 02393190 |
| VOLTAREN EMULGEL JOINT PAIN EXTRA STRENGTH | 2.32 % | GEL | HALEON CANADA ULC | MARKETED | 02465043 |
| VOLTAREN EMULGEL JOINT PAIN REGULAR STRENGTH | 1.16 % | GEL | HALEON CANADA ULC | MARKETED | 02338580 |
| APO-DICLOFENAC | 1.5 % | SOLUTION | APOTEX INC | APPROVED | 02354403 |
| DICLOFENAC DIETHYLAMINE GEL EXTRA STRENGTH | 2.32 % | GEL | TARO PHARMACEUTICALS INC | APPROVED | 02555263 |
2 · Same class — other molecules in ATC M02AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Diclofenac | APO-DICLOFENAC · DICLOFENAC DIETHYLAMINE GEL EXTRA STRENGTH · DICLOFENAC SODIUM SOLUTION · DICLOFENAC TOPICAL SOLUTION · +10 more | 14 | 8 | Yes |
| Bufexamac | NORFEMAC CREAM - 5% · NORFEMAC OINTMENT - 5% | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M02AC | Preparations With Salicylic Acid Derivatives | 120 | 11 |
| M02AB | Capsaicin · Capsaicin And Similar Agents · Zucapsaicin | 26 | 0 |
| M02AX | Dimethyl Sulfoxide · Various | 60 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PMS-DICLOFENAC called?
The same molecule, Diclofenac, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CLOFENE | Latin | Morocco |
| VOLTARENE | Latin | Morocco |
| DIFAL | Latin | Morocco |
| XENID | Latin | Morocco |
| CATAFLAM | Latin | Morocco |
| DICLOBERL | Latin | Morocco |
| Diclofenac Sandoz | Latin | Australia |
| DICLOFENAC-WGR | Latin | Australia |
| DICLOMAX | Latin | Morocco |
| Fenac EC | Latin | Australia |
| Voltaren | Latin | South Africa |
| Voltaren Emulgel | Latin | South Africa |
| FENAC PROMOPHARM | Latin | Morocco |
| Panamor Gel | Latin | South Africa |
| PHARMAFLAM | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.